Interventional Glaucoma

The focus in recent years has shifted to reducing the long-term burden of medical therapy, minimizing the risk of medication toxicity and persistent ocular surface disease.

The new first-line laser treatment for glaucoma and ocular hypertension will be unveiled at the 2025 American Glaucoma Society annual meeting in Washington, DC, from February 26 to March 2.

At the Envision Summit 2025 in San Juan, Puerto Rico, Rachel Simpson, MD, talked about new developments in glaucoma treatment and really how to tailor glaucoma treatment to the patient.

At the Envision Summit 2025 in San Juan, Puerto Rico, Jessica Steen, OD, FAAO talked with glaucoma surgeons on the importance of comanaging patients throughout their lifetime.

Yvonne Ou, MD, a professor of ophthalmology at the University of California San Francisco, spoke about lifestyle modifications for glaucoma at this year's Glaucoma 360 meeting.

The 2 phase II trials, Osprey and Apteryx successfully met all primary and secondary endpoints.

M. Roy Wilson, presented the Shaffer-Hetherington-Hoskins Lecture at the Glaucoma 360 meeting held in San Francisco, California. This lecture was entitled, "Rethinking Race as a Risk Factor for Glaucoma: What Really Matters?"

Ophthalmology Times spoke with Sarah M. Thomasy, DVM, PhD, DACVO, a veterinary ophthalmologist at UC Davis about how her research can align with human glaucoma research to move the entire field

Sunita Radhakrishnan, MD, shares insights on the use of electric neurostimulation and its potential use in the treatment of glaucoma, as evidenced by its current use in Europe and the upcoming trials for use in the US.

Shan Lin, MD, speaks to the new MIGS entering the glaucoma space and providing additional options for patients and providers as they work to preserve vision and work towards a better future for glaucoma treatment options.

Andrew Iwach, MD, co-founder of the Glaucoma 360 meeting shares that value this meeting has for residents and fellows as they embark on their careers and the future additions to the meeting that will include retina discussions.

Patients’ near visual needs is important when prescribing medications for glaucoma treatment

Real-world scenarios showcase a shift in treatment paradigms

Through its ophthalmic program, Mercy Ships provides critical eye surgeries and trains local professionals, ensuring sustainable eye care for the future.

Recipients will be awarded $100,000 to support a collaborative project related to glaucoma

The iDose platform is designed to address ubiquitous patient non-adherence and chronic side effects associated with topical medications by providing 24/7 release of medication.

The long-term analysis show clinically and statistically significant reductions in intraocular pressure through up to 36 months postoperatively.

The campaign will spotlight educational resources and share stories of individuals and families living with glaucoma to raise awareness and encourage proactive eye health management.

These resources include downloadable fact sheets, glaucoma financial assistance resources, shareable social media graphics, and a dedicated webpage.

The 14th annual Glaucoma 360 conference, co-founded by Adrienne Graves, PhD, and Andrew Iwach, MD, and hosted by Glaucoma Research Foundation, will be held from February 6-8, 2025, at the Westin St. Francis in San Francisco, California. The event will focus on the latest advancements in glaucoma care and encourage innovation and collaboration.

Iantrek’s CREST Registry reports 1-year outcomes for a bio-interventional glaucoma treatment, demonstrating significant IOP reduction, medication reduction, and a favorable safety profile, offering a promising new approach for open-angle glaucoma management.

Bausch + Lomb announced the acquisition of the ELIOS system, a laser-based technology that offers a new approach to treating glaucoma, particularly in conjunction with cataract surgery.

According to researchers, GPT-4o demonstrates potential in generating comprehensive differential glaucoma diagnoses but falls short in primary diagnostic accuracy, underscoring its role as a complementary tool rather than a standalone diagnostic solution.

PolyActiva’s phase 2 clinical trial of its PA5108 glaucoma implant met efficacy and safety end points, demonstrating more than 20% reduction in IOP. The biodegradable implant offers sustained drug delivery for up to 26 weeks, addressing challenges of patient adherence and improving glaucoma treatment outcomes.

While studies of obesity and tobacco and alcohol consumption showed that many chronic diseases are affected by the factors being studied, none had mentioned an effect on glaucoma progression.